NYSE$BSX
Boston Scientific Corp · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Boston Scientific's financial performance exceeded expectations, driven by growth across all segments and regions.
Boston Scientific reported net sales of $3.244 billion for Q2 2022, representing a 5.4% increase on a reported basis and a 6.6% increase on an organic basis compared to the prior year period. The company's GAAP net income available to common stockholders was $246 million, or $0.17 per share, while adjusted EPS reached $0.44.
- Net sales grew by 5.4% on a reported basis, 9.6% on an operational basis, and 6.6% on an organic basis compared to the prior year period.
- GAAP net income available to common stockholders was $0.17 per share, and adjusted EPS was $0.44 per share.
- Net sales growth was achieved in each reportable segment compared to the prior year period.
- FDA 510(k) clearance received for the VersaCross Connect™ LAAC Access Solution.
Headline financials
Revenue & EPS history
Boston Scientific · Revenue · Quarterly
$3.24B
Revenue by segment
Boston Scientific · $3.24B total across 2 segments · Q2 2022
- Cardiovascular$2B+58.0%61.5%
- MedSurg$1.25B+31.6%38.5%
Forward guidance
The company estimates net sales growth for the full year 2022 to be in a range of approximately 6.5 to 7.5 percent on a reported basis and estimates EPS on a GAAP basis in a range of $0.69 to $0.76 and adjusted EPS of $1.74 to $1.77. The company estimates net sales growth for the third quarter of 2022 to be in a range of approximately 6 to 8 percent on a reported basis and estimates EPS on a GAAP basis in a range of $0.20 to $0.24 and adjusted EPS of $0.43 to $0.45.
Tailwinds
- Full year 2022 net sales growth is expected to be approximately 6.5 to 7.5 percent on a reported basis.
- Full year 2022 organic net sales growth is expected to be approximately 8 to 9 percent.
- Full year 2022 EPS on a GAAP basis is estimated to be in a range of $0.69 to $0.76.
- Full year 2022 adjusted EPS is estimated to be in a range of $1.74 to $1.77.
- Third quarter 2022 net sales growth is expected to be approximately 6 to 8 percent on a reported basis.
Headwinds
- Foreign currency fluctuations are expected to negatively impact net sales growth.
- Acquisitions and divestitures may impact net sales growth.
- The ongoing COVID-19 pandemic could impact operations and financial results.
- U.S. and global economic conditions could impact performance.
- Manufacturing, distribution, and supply chain disruptions could affect results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+0.8%
Avg return
30 days after
64%
47 / 73 earnings
Positive
+14.0%
Q2 2013
Best reaction
-17.4%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.0% | +0.7% | -3.0% | |
| Q4 2025 | -17.4% | -19.1% | -22.1% | |
| Q3 2025 | +4.0% | +2.5% | -3.0% | |
| Q2 2025 | +0.5% | -1.9% | +0.6% | |
| Q1 2025 | +4.0% | +7.5% | +9.9% | |
| Q4 2024 | +1.4% | +2.5% | -4.3% | |
| Q3 2024 | -3.3% | -3.7% | +2.3% | |
| Q2 2024 | -5.5% | -3.8% | +0.7% | |
| Q1 2024 | +6.2% | +5.1% | +9.6% | |
| Q4 2023 | +5.5% | +4.9% | +9.3% | |
| Q3 2023 | -0.9% | +2.4% | +11.3% | |
| Q2 2023 | -1.4% | -1.0% | -3.1% | |
| Q1 2023 | +1.8% | +3.3% | -0.1% | |
| Q4 2022 | +3.9% | +3.0% | +3.4% | |
| Q3 2022 | +0.7% | +4.4% | +6.9% | |
| Q2 2022 | +8.4% | +8.1% | +6.7% | |
| Q1 2022 | +0.3% | -2.3% | -3.3% | |
| Q4 2021 | -2.0% | -1.4% | +1.1% | |
| Q3 2021 | -2.4% | -3.4% | -13.0% | |
| Q2 2021 | +3.3% | +3.7% | +1.6% | |
| Q1 2021 | +4.0% | +2.9% | +0.3% | |
| Q4 2020 | +5.8% | +8.0% | +7.9% | |
| Q3 2020 | -7.1% | -4.2% | -6.8% | |
| Q2 2020 | +1.8% | -0.7% | +7.2% | |
| Q1 2020 | +4.3% | -0.3% | +5.7% | |
| Q4 2019 | +0.3% | -1.5% | -12.3% | |
| Q3 2019 | +6.2% | +8.9% | +9.6% | |
| Q2 2019 | -2.0% | -1.4% | -4.0% | |
| Q1 2019 | +2.9% | +2.3% | +7.2% | |
| Q4 2018 | +2.9% | +4.1% | +4.7% | |
| Q3 2018 | +1.0% | -1.8% | -3.4% | |
| Q2 2018 | +2.3% | -1.9% | +3.4% | |
| Q1 2018 | +3.3% | +0.8% | +6.4% | |
| Q4 2017 | -2.0% | -4.4% | -4.3% | |
| Q3 2017 | -3.7% | -5.0% | -3.2% | |
| Q2 2017 | -1.5% | -3.4% | -2.6% | |
| Q1 2017 | +1.6% | +2.4% | +5.2% | |
| Q4 2016 | +5.3% | +5.3% | +4.3% | |
| Q3 2016 | -4.2% | -2.0% | -5.7% | |
| Q2 2016 | +2.6% | +2.2% | +1.3% | |
| Q1 2016 | +10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.1% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | -2.2% | — | — | |
| Q4 2014 | +3.3% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.7% | — | — | |
| Q1 2014 | -7.1% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -5.5% | — | — | |
| Q2 2013 | +14.0% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +6.6% | — | — | |
| Q3 2012 | -7.1% | — | — | |
| Q2 2012 | -2.1% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | -6.1% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2010 | +6.2% | — | — | |
| Q3 2010 | +4.6% | — | — | |
| Q2 2010 | +0.9% | — | — | |
| Q1 2009 | -5.6% | — | — | |
| Q1 2010 | -0.3% | — | — | |
| Q4 2007 | +0.5% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +3.2% | — | — | |
| Q3 2008 | +3.2% | — | — | |
| Q4 2008 | +1.3% | — | — | |
| Q2 2009 | +1.3% | — | — | |
| Q2 2008 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro